(Q34002880)

30 July 2017

1 reference

title

Anti-idiotype vaccines for human follicular lymphoma (English)

1 reference

30 July 2017

Bendandi M

1

1 reference

30 July 2017

publication date

1 August 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

14

1 reference

30 July 2017

issue

8

1 reference

30 July 2017

page(s)

1333-1339

1 reference

Tumor antigens recognized by T lymphocytes

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Immunity to Oncogenic Proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Human tumor antigens are ready to fly.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

T cell mediated immunotherapy for B cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Prospects for the treatment of B cell tumors using idiotypic vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Myeloma proteins as tumor-specific transplantation antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

The natural history of initially untreated low-grade non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Biologic therapy for lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Development of vaccine strategies for the treatment of B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Cancer vaccine strategies get bigger and better

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Idiotypic DNA vaccines against B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Tumor Immunity Induced by Preimmunization With BALB/c Mouse Myeloma Protein2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Mouse x human heterohybridomas as fusion partners with human B cell tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

DNA immunization induces protective immunity against B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Gene therapy of B-cell lymphoma with cytokine gene-modified trioma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Mobilizing dendritic cells for tolerance, priming, and chronic inflammation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401861

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2401861

1 reference

Dimensions Publication ID

30 July 2017

1037840542

0 references

1 reference